Pleuropulmonary and Lymph Node Progression after Docetaxel – Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer

INTRODUCTION: To date, there are no guidelines for a rational and more favourable sequence of treatment after docetaxel. Two drugs (cabazitaxel and abiraterone) have recently been approved as second-line treatment after docetaxel failure in metastatic castration-resistant prostate cancer (mCRPC), bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Huerta, Angel Segura, Santos, Encarnación Reche, Campos, Gema Bruixola, Coloma, Carmen Salvador, Gómez, Oscar Niño
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: July, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728618/
https://www.ncbi.nlm.nih.gov/pubmed/23904851
http://dx.doi.org/10.1159/000354089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728618/
https://www.ncbi.nlm.nih.gov/pubmed/23904851
http://dx.doi.org/10.1159/000354089

Ejemplares similares